L3VLUP
ProSign in

ADMA · ARGX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ADMAARGX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ADMA
  • ARGX
0102030202120222023202420252026
Holders and value by quarter
QuarterADMAARGX
Q3 20202 holders, $6.2m8 holders, $3.6bn
Q4 2020none listed holders, n.a.7 holders, $4.1bn
Q1 2021none listed holders, n.a.8 holders, $4.1bn
Q2 2021none listed holders, n.a.9 holders, $4.6bn
Q3 2021none listed holders, n.a.8 holders, $4.5bn
Q4 2021none listed holders, n.a.9 holders, $5.3bn
Q1 20221 holders, $4.2m8 holders, $5.3bn
Q2 20221 holders, $4.3m13 holders, $6.5bn
Q3 20221 holders, $4.9m14 holders, $5.3bn
Q4 20222 holders, $7.4m13 holders, $5.5bn
Q1 20231 holders, $678k13 holders, $5.9bn
Q2 20232 holders, $11m18 holders, $6.6bn
Q3 20231 holders, $11m21 holders, $8.7bn
Q4 20232 holders, $13m17 holders, $6.3bn
Q1 20244 holders, $62m13 holders, $6.8bn
Q2 20246 holders, $225m14 holders, $7.9bn
Q3 20248 holders, $378m13 holders, $10.7bn
Q4 20247 holders, $209m14 holders, $12.3bn
Q1 20257 holders, $187m17 holders, $11.8bn
Q2 20256 holders, $88m18 holders, $10.8bn
Q3 20254 holders, $221m16 holders, $13.8bn
Q4 20258 holders, $464m16 holders, $14.8bn
Q1 20263 holders, $106m11 holders, $12.3bn
Q2 20261 holders, $73m14 holders, $15.0bn
ADMA

Adma Biologics Inc

Holders
6
Reported value
$225m
Buyers
5
Sellers
1

Breadth +4 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
ARGX

Argenx Se

Holders
14
Reported value
$7.9bn
Buyers
9
Sellers
7

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q2 2024

Among the 20 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only ADMA (6)

Caxton Associates LLP, D. E. Shaw & Co., Renaissance Technologies LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC

Only ARGX (14)

Artisan Partners LP, Capital World Investors, Citadel Advisors LLC, ExodusPoint Capital Management LP, Fidelity (FMR LLC), Holocene Advisors LP, Hudson Bay Capital Management LP, Janus Henderson Group Ltd, Marshall Wace LLP, Moore Capital Management LP, Point72 Asset Management LP, T. Rowe Price Associates Inc, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →